Earnings summaries and quarterly performance for ProPhase Labs.
Executive leadership at ProPhase Labs.
Board of directors at ProPhase Labs.
Research analysts who have asked questions during ProPhase Labs earnings calls.
Recent press releases and 8-K filings for PRPH.
ProPhase Labs Initiates Strategic Processes for BE-Smart™ and Crown Medical Collections
PRPH
New Projects/Investments
M&A
- ProPhase Labs has initiated a potential sale or strategic partnership process for its BE-Smart™ esophageal cancer risk stratification test, with the objective of generating significant liquidity and strengthening the Company’s balance sheet.
- The Company has begun targeted outreach to over 70 potential acquirers and strategic partners for BE-Smart™, which has an estimated addressable market opportunity of up to $14 billion annually.
- ProPhase is also advancing its Crown Medical Collections initiative to recover unpaid and underpaid COVID-19 diagnostic testing claims, noting that over 60% of the aggregate claim universe consists of partially reimbursed commercial payer claims, which is expected to strengthen recovery prospects.
- Both initiatives are anticipated to provide significant liquidity and materially improve the Company's financial position.
4 days ago
ProPhase Labs to Host Investor Webinar on February 3rd, Highlighting BE-Smart Esophageal Cancer Test and Strategic Initiatives
PRPH
Product Launch
New Projects/Investments
- ProPhase Labs (OTC: PRPH) is inviting investors to a webinar on Tuesday, February 3, 2026, at 4:15 p.m. ET, featuring Chairman and CEO Ted Karkus.
- The webinar will highlight the full U.S. patent approval and clinical validation of its BE-Smart \u2122 Esophageal Cancer Test, which addresses a $7\u201314 billion market.
- Discussions will also include a strategic initiative with Crown Medical Collections to recover over $50 million in COVID-19 receivables and the consumer genomics business Nebula Genomics.
- Near-term catalysts include the planned commercialization of BE-Smart \u2122 and the expansion of DNA Complete \u00ae and DNA Expand \u2122 product lines.
5 days ago
ProPhase Labs Provides Crown Medical Collections Update
PRPH
Legal Proceedings
New Projects/Investments
Guidance Update
- ProPhase Labs, Inc. provided an operational update on its Crown Medical Collections initiative, which is focused on recovering legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings.
- Crown Medical is actively engaged in settlement negotiations with over 250 insurance payors, with approximately 50 matters in advanced settlement posture.
- Resolutions for these advanced matters are anticipated within the next 30 to 90 days, expected to generate substantial proceeds and materially enhance near-term liquidity.
- Aggregate net cash recoveries to the company from these efforts, after contingency fees and legal costs, could exceed $50 million.
Jan 27, 2026, 4:06 PM
ProPhase Labs Reports Progress on COVID-19 Testing Receivables Recovery
PRPH
Legal Proceedings
New Projects/Investments
Guidance Update
- ProPhase Labs' Crown Medical Collections initiative is actively engaged in settlement negotiations with over 250 insurance payors regarding outstanding COVID-19 testing receivables.
- Approximately 50 matters are in advanced settlement posture, with resolutions expected within the next 30 to 90 days, which are anticipated to generate substantial proceeds and materially enhance near-term liquidity.
- The company's laboratory subsidiaries had approximately $150 million in unpaid or underpaid COVID-19 testing claims out of $300 million in total gross billings.
- Aggregate net cash recoveries from these efforts are estimated to exceed $50 million after contingency fees and legal costs.
- Initial settlements are expected in Q1 2026, following the Chapter 11 reorganization of the laboratory subsidiaries to streamline these recovery efforts.
Jan 26, 2026, 12:00 PM
ProPhase Labs, Inc. Details Warrant Issuance and Equity Line Agreement
PRPH
- ProPhase Labs, Inc. issued a Common Stock Purchase Warrant for 240,369 shares to Generating Alpha Ltd. on January 16, 2025, with an exercise price of $0.00.
- The Company has not yet paid 789,474 shares of common stock as Commitment Shares, which are fully earned and non-refundable.
- The net proceeds from this offering will be used for working capital and other general corporate purposes, including transaction fees and commissions.
- ProPhase Labs, Inc. is committed to maintaining the listing of its Common Stock on the OTC QB or higher and fulfilling its reporting obligations under the Exchange Act.
Jan 23, 2026, 10:15 PM
PVP Labs to Present TAPHALGIN® Analgesic Platform at JP Morgan Healthcare Conference 2026
PRPH
Product Launch
New Projects/Investments
M&A
- PVP Labs will present its TAPHALGIN® Tetrapeptide Analgesic Platform at the JP Morgan Healthcare Conference 2026, highlighting its potential as an innovative, non-addictive analgesic.
- TAPHALGIN® is a dual-mechanism tetrapeptide engineered for rapid, clinically meaningful pain relief while reducing opioid-associated risks.
- The platform has been in development for over 10 years, evaluated across six clinical trials, and supported by over 100,000 documented human exposures from real-world international use, where it is already approved outside the United States for acute postoperative and cancer-related pain.
- PVP Labs is actively pursuing strategic partnerships, including co-development, regional or global licensing, and potential acquisition opportunities, as it advances TAPHALGIN® toward U.S. clinical development.
Jan 12, 2026, 8:11 PM
ProPhase Labs Updates on Capital Structure and Debt Conversions
PRPH
Debt Issuance
Delisting/Listing Issues
- ProPhase Labs announced that more than $3.3 million of its convertible debt principal has been converted out of $3.8 million at issuance, resulting in a corresponding reduction in company debt and an increase in shareholders’ equity.
- The vast majority of this conversion activity is now complete, with less than $500,000 of the principal balance remaining unconverted.
- The company attributed recent stock price volatility to these debt conversions, a 1-for-10 reverse stock split effective December 5, 2025, and its transition from Nasdaq to the OTC market effective January 5, 2026.
- Management believes the potential for additional conversion-related selling pressure is significantly reduced, as recent conversions occurred at a stated floor price of approximately $0.76 per share.
Jan 9, 2026, 10:15 PM
ProPhase Labs Updates on Convertible Debt Conversions and Capital Structure
PRPH
Delisting/Listing Issues
- ProPhase Labs (OTC: PRPH) announced that more than $3.3 million of its convertible debt principal has been converted out of $3.8 million at issuance, significantly reducing company debt and strengthening its balance sheet.
- The company attributes recent stock volatility to short-term technical factors, including these debt conversions, a 1-for-10 reverse stock split, and its transition from Nasdaq to the OTC market.
- The vast majority of the convertible debt conversion is now complete, with less than $500,000 remaining unconverted, and management believes potential for additional conversion-related selling pressure is significantly reduced due to a stated floor conversion price of approximately $0.76 per share.
- Management asserts that the current market capitalization reflects a short-term technical dislocation rather than the intrinsic value of its core assets, which include Crown Medical receivables, the BE-Smart Esophageal Cancer diagnostic test, and Nebula Genomics / DNA Complete.
Jan 5, 2026, 10:00 AM
ProPhase Labs, Inc. to be Delisted from Nasdaq
PRPH
Delisting/Listing Issues
- ProPhase Labs, Inc. (PRPH) received a Nasdaq staff determination letter on December 29, 2025, indicating it failed to regain compliance with the minimum bid price requirement of $1.00 per share.
- As a result, trading of the company's common stock will be suspended at the opening of business on January 5, 2026, and Nasdaq will proceed with delisting its securities from The Nasdaq Stock Market.
- The company intends to appeal the delisting decision by requesting a hearing before the Nasdaq Hearings Panel and is applying for quotation of its common stock on the OTC Markets.
Jan 2, 2026, 10:10 PM
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
PRPH
M&A
Dividends
- ProPhase Labs, Inc. (PRPH) and Advanced Biological Laboratories S.A. (ABL) have signed a non-binding Letter of Intent (LOI) for a proposed reverse merger transaction, announced on December 19, 2025.
- Under the proposed terms, ABL would become the majority owner, holding approximately 76% of the combined company.
- The LOI includes a preliminary, non-binding valuation framework for the legacy ProPhase business of up to approximately $30 million.
- Current ProPhase shareholders may receive a special cash dividend of up to $10 million and benefit from the carve-out of Crown Medical Collections receivables, with anticipated net collections of approximately $50 million.
- The parties anticipate working towards execution of definitive documentation within approximately 60 to 90 days from the announcement date.
Dec 19, 2025, 8:37 PM
Quarterly earnings call transcripts for ProPhase Labs.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more